Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001509633 | SCV001716458 | benign | not provided | 2025-02-04 | criteria provided, single submitter | clinical testing | |
Institute for Clinical Genetics, |
RCV001509633 | SCV002010655 | uncertain significance | not provided | 2021-11-03 | criteria provided, single submitter | clinical testing | |
Ce |
RCV001509633 | SCV003916110 | benign | not provided | 2025-01-01 | criteria provided, single submitter | clinical testing | FBXO11: BS1, BS2 |
Prevention |
RCV003405461 | SCV004114382 | uncertain significance | FBXO11-related disorder | 2023-08-02 | criteria provided, single submitter | clinical testing | The FBXO11 c.167_169dupAGC variant is predicted to result in an in-frame duplication (p.Gln56dup). To our knowledge, this variant has not been reported in the literature. This variant is reported in 1.4% of alleles in individuals of Ashkenazi Jewish descent in gnomAD (http://gnomad.broadinstitute.org/variant/2-48132690-G-GGCT), however this variant is found within a low complexity region of the genome and frequency data should be interpreted with caution. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Centre de Biologie Pathologie Génétique, |
RCV001252491 | SCV001428248 | likely benign | Intellectual disability | 2019-01-01 | no assertion criteria provided | clinical testing | |
Diagnostic Laboratory, |
RCV001509633 | SCV001740744 | likely benign | not provided | no assertion criteria provided | clinical testing | ||
Laboratory of Diagnostic Genome Analysis, |
RCV001509633 | SCV001798310 | likely benign | not provided | no assertion criteria provided | clinical testing |